Figure 3

Projected prescription drug expenditures for ADHD in children and adolescents, 2001 – 2012 (base case). a, b: Defined daily doses (DDDs) p.a.; c, d: expenditures by category p.a.; e, f: total (cumulated) expenditures p.a.; left: England; right: Germany. MPH: methylphenidate; IR: immediate-release formulations (Ritalin^R, branded generics [Equasym^R, Medikinet^R], generics; Focalin^R); MR: modified-release formulations (Concerta^R XL, Equasym^R XL, Medikinet^R retard, Focalin^R XR; MPH-Patch: transdermal system (Daytrana^R); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: atomoxetine (Strattera^R), armodafinil (Nuvigil^R); DEX: dexamphetamine (England only).